Search
forLearn
5 / 801 resultslearn TDM-105795
learn dl-alpha-tocopherol
learn HT-B
learn Dextran
Research
5 / 1000+ results
research Chemical Reactions Occurring in Curing Treatment for Permanent Hair Straightening Using Thioglycolic and Dithioglycolic Acids
Using both TGA and DTDG in hair straightening reduces hair damage compared to using TGA alone.
research Structural Changes of Hair Keratin by Reduction, Heat and subsequent Oxidation Treatments
DTDG in hair treatments reduces damage and preserves hair structure.
research Preparation of Water Soluble Wool Keratin and Its Application for Human Hair
Water-soluble wool keratin can protect human hair from damage during treatments.
research Targeted Inactivation of Gh/Tissue Transglutaminase II
Tgm2 helps stabilize dying cells and aids fibroblast attachment to the extracellular matrix.
research Photosensitive Trichothiodystrophy with Complex Cerebral Abnormalities
Trichothiodystrophy is a rare genetic disorder causing hair issues and sometimes linked to DNA repair defects.
Community Join
5 / 1000+ resultscommunity PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community Any experiences with Ptd-dbm??
The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.
community How much do we know about PTD-DBM?
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.